Abstract

Because results with conventional salvage therapy remain disappointing, the approach of using high-dose therapy and bone marrow transplantation has gained increasing support in recent years. Several trials have now been reported using various conditioning regimens and hematopoietic rescue sources. Although it is not clear which high-dose chemotherapy is the best conditioning regimen, many of the trials contain patients who are long-term disease-free survivors using this therapeutic approach. As more experience is gained with this therapy, the patient population for which it offers the best results will be better defined. High-dose therapy and bone marrow transplantation has been shown to offer better long-term disease-free survival to patients who are transplanted after failing one or two chemotherapy regimens, have good performance status, and still have chemotherapy-sensitive disease. For research to continue in this area, it is important that patients who are otherwise eligible for high-dose therapy and bone marrow transplantation participate in clinical trials to address the unanswered questions concerning high-dose therapy and bone marrow transplantation.

Original languageEnglish (US)
Pages (from-to)749-757
Number of pages9
JournalSeminars in Oncology
Volume17
Issue number6
StatePublished - Dec 1990

Fingerprint

Bone Marrow Transplantation
Hodgkin Disease
Drug Therapy
Therapeutics
Salvage Therapy
Disease-Free Survival
Survivors
Clinical Trials
Research
Population

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Hodgkin's disease : The role of bone marrow transplantation. / Vose, Julie Marie; Bierman, Philip Jay; Armitage, James Olen.

In: Seminars in Oncology, Vol. 17, No. 6, 12.1990, p. 749-757.

Research output: Contribution to journalArticle

@article{1cb506279642429480bf984e6623c1d5,
title = "Hodgkin's disease: The role of bone marrow transplantation",
abstract = "Because results with conventional salvage therapy remain disappointing, the approach of using high-dose therapy and bone marrow transplantation has gained increasing support in recent years. Several trials have now been reported using various conditioning regimens and hematopoietic rescue sources. Although it is not clear which high-dose chemotherapy is the best conditioning regimen, many of the trials contain patients who are long-term disease-free survivors using this therapeutic approach. As more experience is gained with this therapy, the patient population for which it offers the best results will be better defined. High-dose therapy and bone marrow transplantation has been shown to offer better long-term disease-free survival to patients who are transplanted after failing one or two chemotherapy regimens, have good performance status, and still have chemotherapy-sensitive disease. For research to continue in this area, it is important that patients who are otherwise eligible for high-dose therapy and bone marrow transplantation participate in clinical trials to address the unanswered questions concerning high-dose therapy and bone marrow transplantation.",
author = "Vose, {Julie Marie} and Bierman, {Philip Jay} and Armitage, {James Olen}",
year = "1990",
month = "12",
language = "English (US)",
volume = "17",
pages = "749--757",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Hodgkin's disease

T2 - The role of bone marrow transplantation

AU - Vose, Julie Marie

AU - Bierman, Philip Jay

AU - Armitage, James Olen

PY - 1990/12

Y1 - 1990/12

N2 - Because results with conventional salvage therapy remain disappointing, the approach of using high-dose therapy and bone marrow transplantation has gained increasing support in recent years. Several trials have now been reported using various conditioning regimens and hematopoietic rescue sources. Although it is not clear which high-dose chemotherapy is the best conditioning regimen, many of the trials contain patients who are long-term disease-free survivors using this therapeutic approach. As more experience is gained with this therapy, the patient population for which it offers the best results will be better defined. High-dose therapy and bone marrow transplantation has been shown to offer better long-term disease-free survival to patients who are transplanted after failing one or two chemotherapy regimens, have good performance status, and still have chemotherapy-sensitive disease. For research to continue in this area, it is important that patients who are otherwise eligible for high-dose therapy and bone marrow transplantation participate in clinical trials to address the unanswered questions concerning high-dose therapy and bone marrow transplantation.

AB - Because results with conventional salvage therapy remain disappointing, the approach of using high-dose therapy and bone marrow transplantation has gained increasing support in recent years. Several trials have now been reported using various conditioning regimens and hematopoietic rescue sources. Although it is not clear which high-dose chemotherapy is the best conditioning regimen, many of the trials contain patients who are long-term disease-free survivors using this therapeutic approach. As more experience is gained with this therapy, the patient population for which it offers the best results will be better defined. High-dose therapy and bone marrow transplantation has been shown to offer better long-term disease-free survival to patients who are transplanted after failing one or two chemotherapy regimens, have good performance status, and still have chemotherapy-sensitive disease. For research to continue in this area, it is important that patients who are otherwise eligible for high-dose therapy and bone marrow transplantation participate in clinical trials to address the unanswered questions concerning high-dose therapy and bone marrow transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0025599939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025599939&partnerID=8YFLogxK

M3 - Article

C2 - 2251520

AN - SCOPUS:0025599939

VL - 17

SP - 749

EP - 757

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 6

ER -